AU2011359350B2 - Compositions and methods of use for determination of HE4a - Google Patents

Compositions and methods of use for determination of HE4a

Info

Publication number
AU2011359350B2
AU2011359350B2 AU2011359350A AU2011359350A AU2011359350B2 AU 2011359350 B2 AU2011359350 B2 AU 2011359350B2 AU 2011359350 A AU2011359350 A AU 2011359350A AU 2011359350 A AU2011359350 A AU 2011359350A AU 2011359350 B2 AU2011359350 B2 AU 2011359350B2
Authority
AU
Australia
Prior art keywords
antibody
he4a
antigen
polypeptide
ovarian cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011359350A
Other languages
English (en)
Other versions
AU2011359350A2 (en
AU2011359350A1 (en
Inventor
Christian Fermer
Ingegerd Hellstrom
Karl-Erik Hellstrom
John Raycraft
Eva ROIJER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PACIFIC NORTHWEST DIABETES RESEARCH INSTITUTE
Fujirebio Diagnostics Inc
Original Assignee
Pacific Northwest Diabetes Res Institute
Fujirebio Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pacific Northwest Diabetes Res Institute, Fujirebio Diagnostics Inc filed Critical Pacific Northwest Diabetes Res Institute
Publication of AU2011359350A1 publication Critical patent/AU2011359350A1/en
Publication of AU2011359350A2 publication Critical patent/AU2011359350A2/en
Assigned to PACIFIC NORTHWEST DIABETES RESEARCH INSTITUTE, FUJIREBIO DIAGNOSTICS, INC reassignment PACIFIC NORTHWEST DIABETES RESEARCH INSTITUTE Amend patent request/document other than specification (104) Assignors: FUJIREBIO DIAGNOSTICS, INC
Application granted granted Critical
Publication of AU2011359350B2 publication Critical patent/AU2011359350B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5755—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the uterine cervix, uterine corpus or endometrium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2011359350A 2011-02-17 2011-02-17 Compositions and methods of use for determination of HE4a Active AU2011359350B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/025321 WO2012112160A1 (en) 2011-02-17 2011-02-17 Compositions and methods of use for determination of he4a

Publications (3)

Publication Number Publication Date
AU2011359350A1 AU2011359350A1 (en) 2013-09-12
AU2011359350A2 AU2011359350A2 (en) 2014-05-01
AU2011359350B2 true AU2011359350B2 (en) 2016-07-14

Family

ID=46672864

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011359350A Active AU2011359350B2 (en) 2011-02-17 2011-02-17 Compositions and methods of use for determination of HE4a

Country Status (12)

Country Link
US (3) US9822169B2 (https=)
EP (1) EP2675911B1 (https=)
JP (1) JP5887364B2 (https=)
KR (3) KR101854110B1 (https=)
CN (1) CN103492582B (https=)
AU (1) AU2011359350B2 (https=)
BR (1) BR112013021056B1 (https=)
CA (1) CA2827618C (https=)
ES (1) ES2834617T3 (https=)
IL (1) IL227924B (https=)
RU (1) RU2650778C2 (https=)
WO (1) WO2012112160A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
RU2650778C2 (ru) * 2011-02-17 2018-04-17 Фуджиребио Диагностикс, Инк Композиции и способы применения для определения не4а
CN106432492A (zh) * 2015-08-07 2017-02-22 广州瑞博奥生物技术有限公司 针对肿瘤标志物建立的抗体组合及其elisa方法
WO2017142025A1 (ja) * 2016-02-19 2017-08-24 国立大学法人宮崎大学 腺癌の検出方法
USD922352S1 (en) 2019-01-04 2021-06-15 Dolby Laboratories Licensing Corporation Speaker
JP7539369B2 (ja) * 2019-04-02 2024-08-23 大塚製薬株式会社 病態情報生成方法、病態情報生成システム、ｈｅ４糖鎖分析キット及びｈｅ４
CN111620939B (zh) * 2019-10-25 2021-01-01 南京市妇幼保健院 一种用于治疗或辅助治疗卵巢癌的多肽zyx36-58
USD940793S1 (en) * 2019-11-22 2022-01-11 Microsoft Corporation Electronic device
US20230243835A1 (en) * 2020-06-23 2023-08-03 Mitsui Chemicals, Inc. Adenocarcinoma detection method, and examination kit
US20240353411A1 (en) * 2022-04-08 2024-10-24 Ajou University Industry-Academic Cooperation Foundation He4 detecting peptide and use thereof
CN117487018B (zh) * 2023-09-27 2024-05-17 武汉爱博泰克生物科技有限公司 抗人附睾分泌蛋白4的兔单克隆抗体及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US7270960B2 (en) 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
CN1784220B (zh) * 2003-05-05 2011-08-03 前体生物药物股份公司 谷氨酰胺酰基和谷氨酸环化酶效应物的应用
JP4744109B2 (ja) 2004-07-20 2011-08-10 トヨタ自動車株式会社 半導体装置とその製造方法
US7553944B2 (en) * 2004-07-21 2009-06-30 The University Of Hong Kong Human virus causing respiratory tract infection and uses thereof
WO2006089125A2 (en) * 2005-02-16 2006-08-24 Dana-Farber Cancer Institute Methods of detecting ovarian cancer
JP5164855B2 (ja) 2006-01-04 2013-03-21 フジレビオ アメリカ、インク． 子宮内膜または子宮癌を評価するためのｈｅ４及びそのほかの生化学的マーカーの使用
MX2008009592A (es) * 2006-01-27 2008-09-08 Tripath Imaging Inc Metodos y composiciones para identificar pacientes con una probabilidad incrementada de tener cancer de ovario.
BRPI0808655A2 (en) * 2007-03-09 2018-10-23 Tripath Imaging, Inc. he4 monoclonal antibodies and methods for their use.
US8455189B2 (en) 2007-03-29 2013-06-04 Jeffrey W. Allard Use of HE4 for assessment of breast cancers
JP6097688B2 (ja) 2010-08-26 2017-03-15 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション 抗ｈｅ４抗体を検出するための方法、ならびにｈｅ４発現細胞と関連する状態の診断および／または予後判定のための方法
RU2650778C2 (ru) * 2011-02-17 2018-04-17 Фуджиребио Диагностикс, Инк Композиции и способы применения для определения не4а
WO2012170513A2 (en) * 2011-06-06 2012-12-13 Women & Infants' Hospital Of Rhode Island He4 based therapy for malignant disease

Also Published As

Publication number Publication date
CA2827618A1 (en) 2012-08-23
CA2827618C (en) 2019-08-06
RU2013142334A (ru) 2015-03-27
US20180057575A1 (en) 2018-03-01
EP2675911A4 (en) 2015-04-01
KR102074141B1 (ko) 2020-02-07
BR112013021056B1 (pt) 2022-03-29
KR20140025348A (ko) 2014-03-04
RU2650778C2 (ru) 2018-04-17
US9822169B2 (en) 2017-11-21
EP2675911B1 (en) 2020-11-04
US20150353629A1 (en) 2015-12-10
JP5887364B2 (ja) 2016-03-16
IL227924A0 (en) 2013-09-30
KR101854110B1 (ko) 2018-05-04
EP2675911A1 (en) 2013-12-25
CN103492582A (zh) 2014-01-01
JP2014507153A (ja) 2014-03-27
BR112013021056A2 (pt) 2016-08-09
US20200325215A1 (en) 2020-10-15
KR20200013118A (ko) 2020-02-05
CN103492582B (zh) 2016-06-22
IL227924B (en) 2019-01-31
KR20180014239A (ko) 2018-02-07
ES2834617T3 (es) 2021-06-18
AU2011359350A2 (en) 2014-05-01
AU2011359350A1 (en) 2013-09-12
WO2012112160A1 (en) 2012-08-23

Similar Documents

Publication Publication Date Title
AU2011359350B2 (en) Compositions and methods of use for determination of HE4a
EP2913673B1 (en) Diagnosis of ovarian carcinoma
RU2312109C2 (ru) Моноклональное антитело и продуцирующая его гибридома
US6770445B1 (en) Methods and compositions for diagnosing carcinomas
JP4813661B2 (ja) 癌を診断するための方法および組成物
US9006396B2 (en) CsPCNA isoform antibodies and uses thereof
JP2006304807A (ja) Ｃ−ｅｒｂＢ−２外部ドメイン：ＧＰ７５
KR101750411B1 (ko) 엑소좀 단백질 eif3a 특이반응 오토항체검출용 항원 조성물 및 이를 이용한 간암진단법
CA2671633C (en) Diagnostic agent for mesothelioma, diagnosis kit for mesothelioma, and diagnosis method for mesothelioma
JP3888695B2 (ja) ヒトｌｅｃｔ２に対する抗体、それを産生する細胞、その測定法及び測定用キット
HK1191056B (en) Compositions and methods of use for determination of he4a
US20040142396A1 (en) Methods and compositions for diagnosing carcinomas
US20110104675A1 (en) Methods and Compositions for Diagnosing Carcinomas
CN117447598A (zh) 一种磷酸化人体pd-l1蛋白特异性抗体及其制备方法和应用
JP2002308900A (ja) 抗ヒト肝性トリグリセリドリパーゼ抗体
HK1214346B (en) Diagnosis of ovarian carcinoma

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTORS TO READ HELLSTROM, INGEGERD; HELLSTROM, KARL-ERIK; RAYCRAFT, JOHN; FERMER, CHRISTIAN AND ROIJER, EVA

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 31 MAR 2014

FGA Letters patent sealed or granted (standard patent)